Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Wet Macular Degeneration | 31 | 2024 | 165 | 10.830 |
Why?
|
Macular Degeneration | 40 | 2024 | 1015 | 7.180 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 38 | 2024 | 662 | 7.070 |
Why?
|
Visual Acuity | 96 | 2024 | 2714 | 6.570 |
Why?
|
Macular Edema | 35 | 2022 | 387 | 6.380 |
Why?
|
Angiogenesis Inhibitors | 59 | 2024 | 2056 | 6.340 |
Why?
|
Recombinant Fusion Proteins | 41 | 2024 | 3740 | 6.010 |
Why?
|
Intravitreal Injections | 54 | 2024 | 402 | 5.670 |
Why?
|
Geographic Atrophy | 13 | 2024 | 92 | 5.580 |
Why?
|
Choroidal Neovascularization | 26 | 2023 | 364 | 4.890 |
Why?
|
Diabetic Retinopathy | 19 | 2022 | 1300 | 3.240 |
Why?
|
Retinal Vasculitis | 5 | 2023 | 46 | 3.110 |
Why?
|
Tomography, Optical Coherence | 45 | 2024 | 2957 | 2.710 |
Why?
|
Vascular Endothelial Growth Factor A | 39 | 2024 | 3514 | 2.400 |
Why?
|
Vitreous Body | 17 | 2020 | 401 | 2.370 |
Why?
|
Fluorescein Angiography | 39 | 2024 | 1086 | 2.310 |
Why?
|
Macula Lutea | 6 | 2019 | 180 | 2.290 |
Why?
|
Retinal Vein Occlusion | 14 | 2019 | 149 | 2.180 |
Why?
|
Subretinal Fluid | 6 | 2024 | 25 | 1.910 |
Why?
|
Eye Diseases | 7 | 2024 | 660 | 1.900 |
Why?
|
Vitrectomy | 13 | 2017 | 392 | 1.870 |
Why?
|
Laser Coagulation | 14 | 2019 | 334 | 1.840 |
Why?
|
Lasers, Solid-State | 3 | 2020 | 183 | 1.560 |
Why?
|
Endophthalmitis | 5 | 2020 | 263 | 1.230 |
Why?
|
Retinal Detachment | 7 | 2016 | 429 | 1.150 |
Why?
|
Retinal Diseases | 7 | 2024 | 710 | 1.140 |
Why?
|
Vision Disorders | 8 | 2020 | 1093 | 1.130 |
Why?
|
Fundus Oculi | 15 | 2021 | 560 | 1.070 |
Why?
|
Double-Blind Method | 41 | 2024 | 12465 | 1.060 |
Why?
|
Retinal Hemorrhage | 2 | 2018 | 98 | 1.050 |
Why?
|
Retina | 17 | 2022 | 2662 | 1.020 |
Why?
|
Ophthalmic Solutions | 6 | 2022 | 312 | 0.950 |
Why?
|
Cataract Extraction | 7 | 2018 | 464 | 0.940 |
Why?
|
Angiopoietin-2 | 2 | 2024 | 186 | 0.920 |
Why?
|
Laser Therapy | 4 | 2020 | 1107 | 0.900 |
Why?
|
Myopia, Degenerative | 2 | 2015 | 14 | 0.870 |
Why?
|
Hawks | 1 | 2022 | 1 | 0.820 |
Why?
|
Antibodies, Bispecific | 2 | 2024 | 204 | 0.820 |
Why?
|
Angioid Streaks | 2 | 2013 | 14 | 0.800 |
Why?
|
Angiopoietins | 1 | 2021 | 86 | 0.710 |
Why?
|
Retinal Artery Occlusion | 1 | 2020 | 83 | 0.680 |
Why?
|
Medical Futility | 1 | 2020 | 136 | 0.630 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 1 | 2019 | 183 | 0.630 |
Why?
|
Treatment Outcome | 59 | 2024 | 65371 | 0.610 |
Why?
|
Immunoglobulin Fab Fragments | 1 | 2020 | 446 | 0.600 |
Why?
|
Antibodies, Monoclonal | 14 | 2022 | 9263 | 0.590 |
Why?
|
Integrins | 1 | 2022 | 842 | 0.590 |
Why?
|
Parvovirinae | 1 | 2017 | 10 | 0.580 |
Why?
|
Diabetes Mellitus | 5 | 2022 | 5889 | 0.580 |
Why?
|
Vitreoretinopathy, Proliferative | 2 | 2016 | 75 | 0.580 |
Why?
|
Aged | 83 | 2024 | 171504 | 0.570 |
Why?
|
Aged, 80 and over | 50 | 2024 | 59629 | 0.570 |
Why?
|
Retinal Vessels | 2 | 2021 | 864 | 0.560 |
Why?
|
Endoscopes | 2 | 2014 | 169 | 0.540 |
Why?
|
Ocular Hypotension | 1 | 2016 | 23 | 0.530 |
Why?
|
Humans | 148 | 2024 | 768166 | 0.520 |
Why?
|
Follow-Up Studies | 32 | 2024 | 39348 | 0.520 |
Why?
|
Central Serous Chorioretinopathy | 1 | 2016 | 32 | 0.520 |
Why?
|
Sickness Impact Profile | 8 | 2020 | 299 | 0.520 |
Why?
|
Retreatment | 9 | 2013 | 598 | 0.500 |
Why?
|
Vancomycin | 1 | 2018 | 506 | 0.490 |
Why?
|
Venous Pressure | 1 | 2015 | 55 | 0.490 |
Why?
|
Basement Membrane | 1 | 2016 | 348 | 0.490 |
Why?
|
Eye Infections | 1 | 2015 | 63 | 0.490 |
Why?
|
Albinism, Oculocutaneous | 1 | 2015 | 19 | 0.490 |
Why?
|
Lenses, Intraocular | 2 | 2015 | 141 | 0.490 |
Why?
|
Photochemotherapy | 5 | 2015 | 830 | 0.490 |
Why?
|
Iris Diseases | 1 | 2015 | 36 | 0.480 |
Why?
|
Hypopigmentation | 1 | 2015 | 43 | 0.480 |
Why?
|
Valsalva Maneuver | 1 | 2015 | 99 | 0.480 |
Why?
|
MAP Kinase Kinase 1 | 1 | 2016 | 331 | 0.470 |
Why?
|
Pigment Epithelium of Eye | 1 | 2015 | 209 | 0.470 |
Why?
|
Fovea Centralis | 3 | 2012 | 126 | 0.460 |
Why?
|
Drug Substitution | 2 | 2016 | 291 | 0.460 |
Why?
|
Male | 94 | 2024 | 364719 | 0.460 |
Why?
|
Retinal Perforations | 4 | 2018 | 138 | 0.460 |
Why?
|
Retinal Neovascularization | 1 | 2017 | 288 | 0.450 |
Why?
|
Pseudoxanthoma Elasticum | 1 | 2013 | 14 | 0.450 |
Why?
|
Emphysema | 1 | 2016 | 236 | 0.440 |
Why?
|
Vitelliform Macular Dystrophy | 1 | 2013 | 18 | 0.440 |
Why?
|
Female | 92 | 2024 | 397192 | 0.410 |
Why?
|
Vitreous Detachment | 3 | 2018 | 23 | 0.410 |
Why?
|
Vascular Endothelial Growth Factors | 2 | 2013 | 748 | 0.400 |
Why?
|
Endotamponade | 4 | 2016 | 37 | 0.400 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 5 | 2009 | 2271 | 0.390 |
Why?
|
Cryosurgery | 2 | 2016 | 479 | 0.390 |
Why?
|
Early Diagnosis | 1 | 2017 | 1194 | 0.390 |
Why?
|
Phenyl Ethers | 2 | 2024 | 62 | 0.380 |
Why?
|
Propanolamines | 2 | 2024 | 164 | 0.370 |
Why?
|
Benzimidazoles | 1 | 2016 | 864 | 0.370 |
Why?
|
Porphyrins | 3 | 2009 | 352 | 0.360 |
Why?
|
Visual Field Tests | 7 | 2022 | 415 | 0.360 |
Why?
|
Middle Aged | 61 | 2024 | 223492 | 0.360 |
Why?
|
Endoscopy | 3 | 2016 | 1854 | 0.350 |
Why?
|
Histoplasmosis | 1 | 2010 | 63 | 0.350 |
Why?
|
Bromobenzenes | 1 | 2009 | 2 | 0.340 |
Why?
|
Choroid | 2 | 2024 | 364 | 0.340 |
Why?
|
Benzeneacetamides | 1 | 2009 | 36 | 0.340 |
Why?
|
Phenylacetates | 1 | 2009 | 112 | 0.330 |
Why?
|
Benzophenones | 1 | 2009 | 57 | 0.330 |
Why?
|
Intraocular Pressure | 9 | 2020 | 1304 | 0.330 |
Why?
|
Disease Management | 1 | 2020 | 2536 | 0.330 |
Why?
|
Ketorolac | 1 | 2009 | 95 | 0.320 |
Why?
|
Uveitis, Anterior | 2 | 2000 | 103 | 0.320 |
Why?
|
Prospective Studies | 30 | 2024 | 54926 | 0.310 |
Why?
|
Photosensitizing Agents | 3 | 2009 | 629 | 0.310 |
Why?
|
Ketorolac Tromethamine | 3 | 2008 | 21 | 0.300 |
Why?
|
Cost Savings | 1 | 2013 | 904 | 0.300 |
Why?
|
Protein Kinase Inhibitors | 1 | 2024 | 5703 | 0.290 |
Why?
|
Phacoemulsification | 3 | 2010 | 151 | 0.280 |
Why?
|
Glucocorticoids | 5 | 2014 | 2167 | 0.280 |
Why?
|
Exercise Test | 1 | 2015 | 2186 | 0.270 |
Why?
|
Cataract | 2 | 2012 | 837 | 0.270 |
Why?
|
Dinoprostone | 1 | 2009 | 597 | 0.270 |
Why?
|
Silicone Oils | 2 | 2016 | 22 | 0.270 |
Why?
|
Fibrinolysin | 2 | 2018 | 130 | 0.260 |
Why?
|
Dose-Response Relationship, Drug | 9 | 2024 | 10760 | 0.250 |
Why?
|
Vitreoretinal Surgery | 2 | 2016 | 28 | 0.250 |
Why?
|
Prednisolone | 2 | 2008 | 326 | 0.240 |
Why?
|
Scleral Buckling | 2 | 2016 | 95 | 0.230 |
Why?
|
Injections, Intraocular | 2 | 2024 | 36 | 0.230 |
Why?
|
Anti-Bacterial Agents | 2 | 2018 | 7477 | 0.210 |
Why?
|
Retinal Pigment Epithelium | 2 | 2021 | 309 | 0.210 |
Why?
|
Sulfur Hexafluoride | 2 | 2013 | 26 | 0.210 |
Why?
|
Dexamethasone | 3 | 2011 | 1965 | 0.200 |
Why?
|
Miosis | 2 | 2015 | 9 | 0.200 |
Why?
|
Color Vision | 1 | 2022 | 23 | 0.200 |
Why?
|
Plasma Kallikrein | 1 | 2021 | 21 | 0.200 |
Why?
|
Drug Implants | 3 | 2011 | 230 | 0.190 |
Why?
|
Monitoring, Ambulatory | 2 | 2016 | 358 | 0.190 |
Why?
|
Peptides, Cyclic | 1 | 2023 | 391 | 0.190 |
Why?
|
Injections | 10 | 2010 | 840 | 0.190 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2024 | 637 | 0.190 |
Why?
|
Glaucoma | 1 | 2011 | 1194 | 0.190 |
Why?
|
Pseudophakia | 1 | 2000 | 61 | 0.180 |
Why?
|
Visual Fields | 4 | 2016 | 1065 | 0.180 |
Why?
|
Drug Administration Schedule | 3 | 2022 | 4860 | 0.180 |
Why?
|
Hyperthermia, Induced | 1 | 2004 | 416 | 0.170 |
Why?
|
Tromethamine | 1 | 1999 | 31 | 0.160 |
Why?
|
Tolmetin | 1 | 1999 | 24 | 0.160 |
Why?
|
Complement Inactivating Agents | 1 | 2019 | 53 | 0.160 |
Why?
|
Adult | 23 | 2024 | 223646 | 0.160 |
Why?
|
Retinal Vein | 1 | 2019 | 47 | 0.160 |
Why?
|
Time Factors | 8 | 2020 | 40218 | 0.160 |
Why?
|
Eye Pain | 2 | 2016 | 46 | 0.160 |
Why?
|
Postoperative Complications | 3 | 2018 | 15832 | 0.150 |
Why?
|
Drug Combinations | 2 | 2016 | 2089 | 0.150 |
Why?
|
Prostaglandins F, Synthetic | 1 | 1998 | 32 | 0.150 |
Why?
|
Retrospective Studies | 18 | 2020 | 81762 | 0.150 |
Why?
|
Drug Therapy, Combination | 4 | 2019 | 6316 | 0.150 |
Why?
|
Complement C3 | 1 | 2019 | 434 | 0.140 |
Why?
|
Inflammation | 2 | 2023 | 10873 | 0.140 |
Why?
|
Drug Approval | 1 | 2024 | 821 | 0.140 |
Why?
|
Fluorocarbons | 2 | 2013 | 506 | 0.140 |
Why?
|
Neurofibroma, Plexiform | 1 | 2017 | 66 | 0.130 |
Why?
|
Exudates and Transudates | 2 | 2014 | 175 | 0.130 |
Why?
|
Air | 1 | 2016 | 187 | 0.130 |
Why?
|
United States Food and Drug Administration | 1 | 2024 | 1673 | 0.130 |
Why?
|
Isoindoles | 1 | 2015 | 36 | 0.130 |
Why?
|
Administration, Topical | 3 | 2009 | 703 | 0.120 |
Why?
|
Receptor-Like Protein Tyrosine Phosphatases, Class 3 | 1 | 2014 | 25 | 0.120 |
Why?
|
Administration, Oral | 2 | 2020 | 4030 | 0.120 |
Why?
|
Immunocompetence | 1 | 1995 | 138 | 0.120 |
Why?
|
Drug Compounding | 1 | 2016 | 241 | 0.120 |
Why?
|
Magnetic Resonance Angiography | 1 | 2021 | 1429 | 0.120 |
Why?
|
Sulfonic Acids | 1 | 2014 | 103 | 0.120 |
Why?
|
Exophthalmos | 1 | 1995 | 100 | 0.110 |
Why?
|
Eye Infections, Fungal | 1 | 1995 | 99 | 0.110 |
Why?
|
Receptor, TIE-2 | 1 | 2014 | 183 | 0.110 |
Why?
|
Carotid Stenosis | 1 | 2021 | 859 | 0.110 |
Why?
|
Europe | 1 | 2020 | 3436 | 0.110 |
Why?
|
Peptide Fragments | 2 | 2018 | 5151 | 0.110 |
Why?
|
Antineoplastic Agents | 1 | 2016 | 13676 | 0.110 |
Why?
|
Surgical Wound Dehiscence | 1 | 1994 | 216 | 0.110 |
Why?
|
Hospitals, Military | 1 | 1993 | 62 | 0.110 |
Why?
|
Incidence | 6 | 2020 | 21538 | 0.110 |
Why?
|
Ankyrin Repeat | 1 | 2012 | 19 | 0.110 |
Why?
|
Chronic Disease | 3 | 2016 | 9384 | 0.110 |
Why?
|
Telemedicine | 3 | 2016 | 3109 | 0.100 |
Why?
|
Biological Availability | 2 | 2012 | 389 | 0.100 |
Why?
|
Prognosis | 5 | 2020 | 30010 | 0.100 |
Why?
|
Neoplasms | 2 | 2024 | 22371 | 0.100 |
Why?
|
Dependovirus | 1 | 2017 | 720 | 0.100 |
Why?
|
Neurofibromatosis 1 | 1 | 2017 | 561 | 0.100 |
Why?
|
Mycoses | 1 | 1995 | 386 | 0.100 |
Why?
|
Indocyanine Green | 1 | 2013 | 239 | 0.100 |
Why?
|
Eye Injuries, Penetrating | 1 | 1993 | 121 | 0.090 |
Why?
|
Eye Injuries | 2 | 2010 | 228 | 0.090 |
Why?
|
Ciliary Neurotrophic Factor | 1 | 2011 | 77 | 0.090 |
Why?
|
Anesthesia, Local | 1 | 2013 | 278 | 0.090 |
Why?
|
Anti-Inflammatory Agents | 1 | 2000 | 1805 | 0.090 |
Why?
|
Coloring Agents | 1 | 2013 | 565 | 0.090 |
Why?
|
United States | 6 | 2024 | 73039 | 0.090 |
Why?
|
Ophthalmoscopy | 1 | 2011 | 172 | 0.090 |
Why?
|
Lens Implantation, Intraocular | 3 | 2008 | 192 | 0.090 |
Why?
|
Blast Injuries | 2 | 2010 | 321 | 0.090 |
Why?
|
Disease Progression | 5 | 2020 | 13671 | 0.090 |
Why?
|
Ligaments | 1 | 2010 | 127 | 0.090 |
Why?
|
Tamoxifen | 1 | 1994 | 966 | 0.080 |
Why?
|
Integrin alpha5beta1 | 1 | 2009 | 36 | 0.080 |
Why?
|
Treatment Failure | 1 | 2016 | 2661 | 0.080 |
Why?
|
Suture Techniques | 1 | 1994 | 775 | 0.080 |
Why?
|
Lenses | 2 | 2008 | 42 | 0.080 |
Why?
|
Eye Proteins | 1 | 2013 | 628 | 0.080 |
Why?
|
Emergency Medical Technicians | 1 | 2010 | 119 | 0.080 |
Why?
|
Exfoliation Syndrome | 1 | 2010 | 113 | 0.080 |
Why?
|
Aniline Compounds | 1 | 2014 | 1094 | 0.080 |
Why?
|
Propionates | 1 | 2009 | 180 | 0.080 |
Why?
|
Drug Delivery Systems | 1 | 2000 | 2232 | 0.080 |
Why?
|
Equipment Design | 2 | 2014 | 3522 | 0.080 |
Why?
|
Diabetes Mellitus, Type 1 | 5 | 2015 | 3447 | 0.070 |
Why?
|
Single-Blind Method | 2 | 2013 | 1587 | 0.070 |
Why?
|
Costs and Cost Analysis | 1 | 2013 | 1667 | 0.070 |
Why?
|
Pyrrolidines | 1 | 2009 | 340 | 0.070 |
Why?
|
Drug Costs | 1 | 2016 | 1195 | 0.070 |
Why?
|
Genetic Vectors | 1 | 2017 | 3402 | 0.070 |
Why?
|
Drug Resistance | 1 | 2013 | 1599 | 0.070 |
Why?
|
Longitudinal Studies | 2 | 2022 | 14783 | 0.070 |
Why?
|
Genetic Markers | 1 | 2013 | 2603 | 0.070 |
Why?
|
Peptides | 2 | 2022 | 4354 | 0.070 |
Why?
|
Microsurgery | 1 | 2011 | 800 | 0.060 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2009 | 1534 | 0.060 |
Why?
|
Sinusitis | 1 | 1995 | 997 | 0.060 |
Why?
|
Eye Infections, Bacterial | 1 | 2008 | 239 | 0.060 |
Why?
|
Tissue Distribution | 1 | 2009 | 2300 | 0.060 |
Why?
|
Health Education | 1 | 2012 | 1059 | 0.060 |
Why?
|
Diagnosis, Differential | 3 | 2015 | 13014 | 0.060 |
Why?
|
Piperazines | 1 | 2015 | 2554 | 0.060 |
Why?
|
DEAE-Dextran | 1 | 2024 | 9 | 0.060 |
Why?
|
Streptococcal Infections | 1 | 2008 | 619 | 0.060 |
Why?
|
Enzyme Inhibitors | 1 | 2014 | 3728 | 0.060 |
Why?
|
Atrophy | 1 | 2009 | 1646 | 0.060 |
Why?
|
Fibrinolytic Agents | 1 | 2013 | 2080 | 0.060 |
Why?
|
Optics and Photonics | 1 | 2005 | 307 | 0.060 |
Why?
|
Prosthesis Implantation | 1 | 2008 | 594 | 0.060 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2009 | 1791 | 0.060 |
Why?
|
Practice Guidelines as Topic | 2 | 2024 | 7454 | 0.060 |
Why?
|
Pyrimidines | 1 | 2015 | 3048 | 0.050 |
Why?
|
Cost-Benefit Analysis | 1 | 2016 | 5536 | 0.050 |
Why?
|
Miniaturization | 3 | 2008 | 154 | 0.050 |
Why?
|
Calcaneus | 1 | 2004 | 144 | 0.050 |
Why?
|
Mass Spectrometry | 1 | 2009 | 2202 | 0.050 |
Why?
|
Fibrosis | 1 | 2009 | 2080 | 0.050 |
Why?
|
Lipoma | 1 | 2004 | 296 | 0.050 |
Why?
|
Ophthalmic Artery | 1 | 2021 | 57 | 0.050 |
Why?
|
Orbit | 2 | 1995 | 459 | 0.050 |
Why?
|
Neurofibromin 2 | 1 | 2022 | 271 | 0.050 |
Why?
|
Emergency Medicine | 1 | 2010 | 1223 | 0.050 |
Why?
|
Health Care Costs | 1 | 2013 | 3239 | 0.040 |
Why?
|
Reoperation | 3 | 2016 | 4329 | 0.040 |
Why?
|
Staphylococcal Infections | 1 | 2008 | 1398 | 0.040 |
Why?
|
Cross-Over Studies | 1 | 2006 | 2107 | 0.040 |
Why?
|
Blood-Retinal Barrier | 1 | 2019 | 63 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2016 | 10399 | 0.040 |
Why?
|
Carotid Artery, Internal | 1 | 2021 | 440 | 0.040 |
Why?
|
Genotype | 1 | 2013 | 13045 | 0.040 |
Why?
|
Anterior Chamber | 1 | 1999 | 194 | 0.040 |
Why?
|
Diabetes Mellitus, Type 2 | 5 | 2015 | 12252 | 0.040 |
Why?
|
Research Design | 1 | 2014 | 6211 | 0.040 |
Why?
|
Pyridines | 1 | 2009 | 2894 | 0.040 |
Why?
|
Signal Transduction | 1 | 2021 | 23645 | 0.040 |
Why?
|
Blood Flow Velocity | 1 | 2021 | 1375 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 3 | 2016 | 20760 | 0.030 |
Why?
|
Carotid Arteries | 1 | 2021 | 942 | 0.030 |
Why?
|
Candida albicans | 1 | 2000 | 375 | 0.030 |
Why?
|
False Positive Reactions | 2 | 2012 | 963 | 0.030 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2011 | 4055 | 0.030 |
Why?
|
Acute Disease | 2 | 2011 | 7243 | 0.030 |
Why?
|
Middle East | 2 | 1993 | 233 | 0.030 |
Why?
|
Quality of Life | 5 | 2023 | 13490 | 0.030 |
Why?
|
Capillaries | 1 | 2019 | 755 | 0.030 |
Why?
|
Mitosporic Fungi | 1 | 1995 | 17 | 0.030 |
Why?
|
Capillary Permeability | 1 | 2019 | 772 | 0.030 |
Why?
|
Endothelium, Corneal | 2 | 2008 | 212 | 0.030 |
Why?
|
Aspergillus | 1 | 1995 | 95 | 0.030 |
Why?
|
Phenotype | 1 | 2013 | 16726 | 0.030 |
Why?
|
Iatrogenic Disease | 1 | 1998 | 552 | 0.030 |
Why?
|
Serotonin Receptor Agonists | 1 | 2015 | 151 | 0.030 |
Why?
|
Safety | 1 | 1999 | 1159 | 0.030 |
Why?
|
Cell Count | 2 | 2008 | 1832 | 0.030 |
Why?
|
Crystallization | 1 | 1994 | 520 | 0.030 |
Why?
|
Injections, Subcutaneous | 1 | 2014 | 687 | 0.030 |
Why?
|
Predictive Value of Tests | 3 | 2012 | 15454 | 0.030 |
Why?
|
Complement Factor H | 1 | 2013 | 110 | 0.030 |
Why?
|
Paranasal Sinuses | 1 | 1995 | 267 | 0.030 |
Why?
|
Tissue Adhesions | 1 | 2013 | 222 | 0.030 |
Why?
|
Aqueous Humor | 1 | 2012 | 152 | 0.020 |
Why?
|
Light | 1 | 1998 | 1355 | 0.020 |
Why?
|
Office Visits | 1 | 2016 | 595 | 0.020 |
Why?
|
Sclerostomy | 1 | 2011 | 16 | 0.020 |
Why?
|
Nasal Mucosa | 1 | 1995 | 416 | 0.020 |
Why?
|
Animals | 2 | 2022 | 169246 | 0.020 |
Why?
|
Glaucoma, Open-Angle | 1 | 1998 | 742 | 0.020 |
Why?
|
Bone Neoplasms | 1 | 2004 | 2565 | 0.020 |
Why?
|
Case Management | 1 | 2013 | 277 | 0.020 |
Why?
|
Clinical Trials as Topic | 2 | 2023 | 8054 | 0.020 |
Why?
|
Apolipoproteins | 1 | 2013 | 328 | 0.020 |
Why?
|
Radiation Injuries | 1 | 1998 | 1198 | 0.020 |
Why?
|
Capsules | 1 | 2011 | 193 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2000 | 6082 | 0.020 |
Why?
|
Cadaver | 1 | 1994 | 1363 | 0.020 |
Why?
|
Maximum Tolerated Dose | 1 | 2012 | 899 | 0.020 |
Why?
|
Disease Models, Animal | 1 | 2009 | 18349 | 0.020 |
Why?
|
Antifungal Agents | 1 | 1995 | 761 | 0.020 |
Why?
|
Complement System Proteins | 1 | 2013 | 738 | 0.020 |
Why?
|
Explosions | 1 | 2010 | 106 | 0.020 |
Why?
|
Epiretinal Membrane | 1 | 2009 | 73 | 0.020 |
Why?
|
Streptococcus mitis | 1 | 2008 | 7 | 0.020 |
Why?
|
Viridans Streptococci | 1 | 2008 | 16 | 0.020 |
Why?
|
Sensory Aids | 1 | 2008 | 40 | 0.020 |
Why?
|
Pain, Postoperative | 1 | 1999 | 1765 | 0.020 |
Why?
|
Staphylococcus epidermidis | 1 | 2008 | 121 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2019 | 5315 | 0.020 |
Why?
|
Sensitivity and Specificity | 3 | 2012 | 14729 | 0.020 |
Why?
|
Absorbable Implants | 1 | 2010 | 337 | 0.020 |
Why?
|
Vision, Ocular | 1 | 2011 | 458 | 0.020 |
Why?
|
Premedication | 1 | 2008 | 246 | 0.020 |
Why?
|
Risk Factors | 5 | 2014 | 74944 | 0.020 |
Why?
|
Terrorism | 1 | 2010 | 211 | 0.020 |
Why?
|
Endpoint Determination | 1 | 2010 | 592 | 0.020 |
Why?
|
Emergencies | 1 | 1993 | 1221 | 0.020 |
Why?
|
Contrast Sensitivity | 1 | 2008 | 253 | 0.020 |
Why?
|
Ultrasonography | 1 | 2000 | 6004 | 0.020 |
Why?
|
Fibronectins | 1 | 2009 | 722 | 0.020 |
Why?
|
Equipment Safety | 1 | 2006 | 250 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 3814 | 0.020 |
Why?
|
Pilot Projects | 2 | 2011 | 8741 | 0.020 |
Why?
|
Registries | 1 | 2020 | 8375 | 0.010 |
Why?
|
Military Personnel | 1 | 1993 | 1261 | 0.010 |
Why?
|
Intraoperative Complications | 1 | 2010 | 1171 | 0.010 |
Why?
|
Wound Healing | 1 | 1994 | 2809 | 0.010 |
Why?
|
Rabbits | 1 | 2009 | 4772 | 0.010 |
Why?
|
Equipment Failure Analysis | 1 | 2005 | 845 | 0.010 |
Why?
|
Cell Adhesion | 1 | 2009 | 3096 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2023 | 26422 | 0.010 |
Why?
|
Photography | 1 | 2005 | 537 | 0.010 |
Why?
|
Optic Disk | 1 | 2006 | 421 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2013 | 8542 | 0.010 |
Why?
|
Reproducibility of Results | 2 | 2013 | 20227 | 0.010 |
Why?
|
Protein Binding | 1 | 2012 | 9343 | 0.010 |
Why?
|
Physical Therapy Modalities | 1 | 2004 | 533 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2009 | 5902 | 0.010 |
Why?
|
Blood Pressure | 1 | 2014 | 8543 | 0.010 |
Why?
|
Prosthesis Design | 1 | 2005 | 2125 | 0.010 |
Why?
|
Proteins | 1 | 2013 | 6009 | 0.010 |
Why?
|
Cell Movement | 1 | 2009 | 5210 | 0.010 |
Why?
|
Postoperative Care | 1 | 2004 | 1480 | 0.010 |
Why?
|
Anterior Eye Segment | 1 | 1998 | 144 | 0.010 |
Why?
|
Activities of Daily Living | 1 | 2006 | 2430 | 0.010 |
Why?
|
Prevalence | 1 | 1994 | 15869 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2009 | 11095 | 0.010 |
Why?
|
Cell Line | 1 | 2009 | 15597 | 0.010 |
Why?
|
Aging | 1 | 2014 | 8744 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2009 | 10474 | 0.010 |
Why?
|
Recurrence | 1 | 2006 | 8509 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2013 | 16045 | 0.010 |
Why?
|
Hospitalization | 1 | 1993 | 10840 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2006 | 15948 | 0.000 |
Why?
|
Breast Neoplasms | 1 | 1994 | 21206 | 0.000 |
Why?
|
Magnetic Resonance Imaging | 1 | 2004 | 36743 | 0.000 |
Why?
|
Infant | 1 | 1993 | 36535 | 0.000 |
Why?
|
Child, Preschool | 1 | 1993 | 42669 | 0.000 |
Why?
|
Child | 1 | 1993 | 80917 | 0.000 |
Why?
|
Adolescent | 1 | 1993 | 89169 | 0.000 |
Why?
|